New US drug delivery research facility opens its doors
Roche Madison Inc officially opened the doors to a new state-of-the-art facility with chemistry and biology labs at the University of Wisconsin Research Park in Madison.
Roche Madison Inc officially opened the doors to a new state-of-the-art facility with chemistry and biology labs at the University of Wisconsin Research Park in Madison.
Part of the global RNA Therapeutics group within Roche, the group's research focuses on the discovery and development of innovative nucleic acid based technologies, including a proprietary RNAi (Ribonucleic Acid interference) delivery platform.
Roche purchased Mirus Bio Corporation, a leader in the fields of RNA interference and gene therapy, which became Roche Madison.
Roche believes RNAi - a natural mechanism that the body uses to 'silence' certain genes - represents a potential whole new class of therapeutics for difficult to treat diseases. The research site currently has a 45-member staff and plans to hire additional staff during the next six to 12 months as part of its planned expansion.